Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be currently receiving aspirin therapy alone or in combination with a thienopyridine per national or local dosing recommendation~* Have been hospitalized for symptoms suggestive of acute coronary syndrome that lasted at least 10 minutes at rest and occurred 48 hours or less before going to the hospital~Exclusion Criteria:~* Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding~* Need for continued anticoagulant therapy~* Significant renal impairment or known significant liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban 2.5 mg bid (Type: EXPERIMENTAL): One 2.5 mg rivaroxaban tablet twice daily for up to 6 months
- Rivaroxaban 5 mg bid (Type: EXPERIMENTAL): One 5 mg rivaroxaban tablet twice daily for up to 6 months
- Placebo (Type: PLACEBO_COMPARATOR): One placebo tablet twice daily for up to 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).